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ABSTRACT 
JASMYN DARDY: Validation of PAK kinases for the Development of Novel 
Therapeutics for Pancreatic Cancer Treatment 
(Under the direction of Channing J. Der) 
 
Pancreatic cancer is the 4th leading cause of cancer deaths in the US and 
essentially all who are diagnosed with this disease will die. Poor patient prognosis is 
largely due to the lack of effective therapies for the disease. There is only one 
approved signal transduction targeted therapy that has had marginal clinical value. 
Thus, there is a dire need for the identification and validation of novel targets that 
contribute to pancreatic tumorigenesis. Evidence points toward the involvement of 
PAK kinases as major effectors in cancer. In this study, my overall goal was to 
determine if I could validate two PAK family kinases, PAK1 or PAK4, as useful 
therapeutic targets for pancreatic cancer.  I found PAK1 and PAK4 protein 
overexpression in pancreatic cancer tissue and/or cell lines and suppression of PAK 
expression can impair pancreatic cancer cell growth. My findings support further 
analysis of PAK as molecular targets and drivers in pancreatic cancer growth. 
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CHAPTER 1.  
INTRODUCTION 
1.1 Pancreatic cancer  
Pancreatic Cancer is one of the most lethal malignancies in the world and the 
4th cause of cancer deaths in the US. Most patients present with advance or 
metastatic disease that is unresectable, impossible to effectively treat, and ultimately 
lethal. In 2012, the American Cancer Society estimates that there will be 43,920 new 
cases, and an estimated 37,390 patients will die from this disease (1). Poor patient 
survival is largely due to the aggressive nature of the disease, advanced stage upon 
diagnosis, and the lack of effective therapies for the disease. Despite the advances 
in our understanding of the molecular biology of the disease, surgical resection 
remains to be the only curative option, and for the few that qualify, many of these 
patients experience recurrence after surgery (2, 3). The cytotoxic agent, 
gemcitabine, provides some benefit for a small fraction of patients, but only modest 
benefit even for those who do respond, in comparison to its efficacy towards other 
cancer types. These poor outcomes associated with conventional cytotoxic therapies 
has driven the cancer field towards the development of molecular targeted therapies, 
that selectively target the molecular aberrations of the disease that are essential for 
cancer survival. 
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To date, the only signal transduction molecularly targeted drug approved for 
pancreatic cancer treatment is the epidermal growth factor receptor (EGFR) inhibitor 
erlotinib (4).  However, the fact that erlotinib was approved for use, in combination 
with gemcitabine based on a two week improvement in survival (median 6.24 
months in combination with erlotinib versus 5.91 months with gemcitabine alone) 
emphasizes disappointing state of therapeutic options for pancreatic cancer. Thus, 
gemcitabine treatment alone remains the standard of care for pancreatic cancer.  
Because of the limited success with the only approved molecular targeted therapy 
for the disease, there is a dire need for the identification and validation of novel 
molecular targets that contribute to pancreatic tumorigenesis. Consequently, a major 
need and focus of pancreatic cancer research is target discovery and validation.  In 
my studies, I have focused on the PAK1 and PAK4 serine/threonine kinases, with 
the goal of providing validation for the importance of PAKs as therapeutic targets for 
pancreatic cancer treatment. 
 
1.2 PAK serine/threonine protein kinases  
Evidence points to the involvement of tyrosine kinase and serine/threonine 
kinase pathways as major effectors in pancreatic cancer development and as 
potential targets for intervention (5). The p21-activated kinase (PAK) family of 
serine/threonine kinases are most well characterized as effectors for the Rho 
GTPases, Rac and Cdc42. Rac and Cdc42 act as molecular switches to regulate 
processes required during metastasis such as invasion and migration through 
extracellular matrix, by interacting with PAKs and initiating the kinase cascade.   
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In pancreatic cancer, Rac may be activated by the K-Ras oncoprotein, that is 
mutated in essentially all pancreatic ductal adenocarcinomas, which comprise ~80% 
of all pancreatic cancers.  K-Ras may activate Rac through two different effectors, 
the p110 catalytic subunit of class IA phosphoinositide 3-kinase (PI3K) or the Rac 
small GTPase guanine nucleotide exchange factor Tiam1. PI3K is a lipid kinase that 
stimulates phospholipid production, in particular, the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
bisphosphate (PIP3).  PIP3 is a membrane-associated lipid that can activate, 
through binding to pleckstrin homology (PH) domains, the AKT serine/threonine 
kinase and other proteins.  One such PH domain-containing protein is a guanine 
nucleotide exchange factor (RhoGEF) for Rac, the related P-Rex1 and P-Rex2 
isoforms.  A second way that K-Ras can activate Rac is through direct binding to 
another RhoGEF, Tiam1, which selectively activates Rac.  That Tiam1 is important 
for RAS-driven cancer development is shown by experiments where a TIAM1 
deficiency reduced the onset of carcinogen (DMBA/TPA)-induced HRAS activation 
and the development of skin carcinomas (6).  That Rac1 is important for KRAS 
driven pancreatic cancer development was shown by studies where a deficiency in 
RAC1, which did not impair normal pancreas growth, did impair pancreatic tumor 
formation (7).  How Rac drives pancreatic cancer growth is currently not known.  
PAK kinases are possible candidates for this role.  
There are six human PAKs identified thus far, subdivided into two groups: 
Group I (Pak1-3) and Group II (Pak4-6). PAK1 is the most studied member of Group 
I and PAK4 is the most studied member of Group II. PAK1 and PAK4 are also both 
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widely expressed. Both groups have a conserved, N-terminal p21 binding domain 
(PBD, also called Rho-binding domain: RBD) and a C-terminal serine/threonine 
kinase domain, but, only Group I possess an autoinhibitory domain (AID), which 
overlaps with the PBD (Figure 1-1).  Rac and Cdc42 are activators of Group I PAKs 
through binding to the PBD. Consequently, Group II PAKs are essentially 
constitutively active while Group I PAKs only reach full activation when activated by 
extracellular signals through GTPase dependent and independent mechanisms, 
under normal cellular conditions (8). The difference in mode of regulation suggests 
different cellular functions. PAKs are most notably known for their role in regulating 
cytoskeletal dynamics and cell motility, but recently they have also been shown to be 
key regulators of cancer cell signaling networks and function as downstream nodes 
for various oncogenic signaling pathways, specifically cellular pathways 
dysregulated in pancreatic cancer. 
 
1.3 PAK and cancer 
Research has implicated upregulated expression and activity of PAKs in 
several human tumor types. PAK1 is the most establish family member in human 
cancers. Initial evidence indicated that exogenously expressed kinase domain-
deleted PAK1 inhibited Ras- and Rac- induced transformation of NIH 3T3 mouse 
fibroblast cells (9). Another study indicated expression of a kinase-dead (K299R) 
PAK1 blocked K-Ras induced transformation of Rat-1 rat fibroblasts, but surprisingly, 
not NIH 3T3 cells (10). PAK1 (K299R) is a dominant-negative that inhibits 
endogenous PAK1 function, presumably by forming inactive homodimer complexes. 
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Ectopic expression of PAK1 (K299R) reversed the ability of activated H-Ras(G12V) 
to reduce proliferation and Matrigel invasion and disrupt human immortalized breast 
MCF-10A epithelial cell ascinar morphology (11).  Finally, ectopic expression of 
PAK1 (K299R) inhibited K-Ras4B growth transformation (soft agar colony formation) 
of SV40 T Ag-immortalized rat Schwann cells (12). DN PAK1 also reduced the soft 
agar growth (80%) and tumor growth of NF1-deficient ST88–14 human 
neuroblastoma cells.  Whether PAK1 is required for human tumor cells with 
endogenously activated mutant Ras has not been determined and is a goal of my 
studies.  
In additional support for a role for PAK 2 in cancer, Balasenthil et al was the 
first group to show increased PAK1 expression in human breast tumors (13). Since 
then, data from several studies indicate that breast tumor cells use various 
mechanisms to upregulate PAK1 signaling for survival advantages and perhaps to 
increase invasive and metastatic potential. Vadlamudi et al was the first to 
demonstrate a direct link between aberrant PAK1 expression and aggressive breast 
cancer cell phenotypes by expressing an inducible, constitutively active PAK1 in 
breast cancer cells (14). The same group also showed in another study that a 
dominant negative form of PAK1 inhibited breast tumor cell invasiveness (15). Wang 
et al was the first to report that PAK1 hyperactivation is sufficient to cause 
mammary-gland tumors in mice suggesting that PAK1 over expression alone is 
sufficient to induce breast tumorigenesis (16).  
Although PAK4 has not been studied as extensively as PAK1, PAK4 is the 
only family member demonstrated to function as an oncogene. Over expression of 
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PAK4 also has been observed in many different types of cancer cell lines and 
tumors including breast, lung, and prostate. PAK4 is chromosomally localized to a 
region commonly amplified in several human colon and ovarian tumors. Ectopic 
expression of constitutively active PAK4 leads to anchorage independent NIH 3T3 
fibroblast cell growth (17) and kinase dead PAK4 inhibits anchorage independent 
growth of a human colon cancer cell line. Furthermore, wild-type and constitutively 
active PAK4 over expression in NIH 3T3 cells stimulated their tumorigenic growth in 
a nude mouse model, suggesting that PAK4 plays a key role in tumorigenesis (18).  
This observation with wild type PAK4 is important since mutated PAK4 alleles have 
not been found in cancer. 
 Providing further evidence for a role for PAKs in cancer has been the 
development and evaluation of small molecule PAK inhibitors.  In one study a PAK4-
selective inhibitor, PF-3758309, showed strong anti-tumor activity when evaluated 
against a variety cancer types (19). However, no evaluation of any pancreatic cancer 
cells was done.  Furthermore, PF-3758309 is not a very selective PAK4 inhibitor, 
with activities on other protein kinases, including PAK1.  Therefore, it is not entirely 
clear how important PAK is in pancreatic tumor biology.  In another study, a PAK1 
selective inhibitor showed potent anti-tumor activity in preclinical cell culture studies 
(20).  This PAK1 inhibitor caused tumor cell apoptosis and was active for both breast 
and lung cancer cells.  No pancreatic cancer cells were tested. 
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1.4 PAK1 and PAK4 in pancreatic cancer 
Although PAK1, PAK4, and other PAK family member have been implicated 
in multiple cancer types, there have been very limited studies investigating the 
specific role of PAKs in pancreatic cancer. In a recent study by Billadeau et al, the 
RhoGEF Vav1, which can activate Rac and Cdc42, contributed to pancreatic cancer 
tumorigenic properties through the regulation of an EGFR-Vav-Rac-PAK1-cyclinD1 
pathway (21). RNAi depletion of Vav1 impaired pancreatic tumor growth in vitro and 
in vivo.  Loss of Vav1 also significantly impaired PAK1 activity, supporting a possible 
role for PAK1 in Vav1-driven pancreatic cancer growth. Because PAK1 has been 
shown to play a key role in other cancer types, PAK1 is most likely responsible for 
the impaired pancreatic cancer cell growth that Billadeau et al attributed to Vav1, 
although this needs to be tested rigorously. Furthermore, three separate studies 
identified PAK4 over expression in pancreatic cancer. Amplification of the PAK4 
locus has been confirmed in pancreatic cancer (22). Additionally, Kimmelman et al 
demonstrated a potential role for PAK4 in pancreatic ductal cell motility and invasion 
(23). I hypothesize that mutant K-Ras-dependent activation of Rac and 
overexpression of PAK1 and PAK4 can promote pancreatic cancer cell growth. In 
my studies, I will first determine if PAK1 or PAK4 protein expression is elevated in 
pancreatic cancer.  If overexpressed, then determine if suppression of PAK 
expression will impair pancreatic tumor growth. 
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CHAPTER 2.  
RESULTS 
2.1 PAK protein expression in pancreatic patient tumors and cell lines 
Previous studies identified PAK1 overexpression in breast, ovarian and 
bladder cancer (24).  To determine if PAK1 is overexpressed in pancreatic cancer, 
we used a PAK1 isoform-specific antibody to assess PAK1 protein expression in cell 
lines and patient tumors.  I examined the protein expression of PAK1 in normal, 
human pancreatic tissue compared to human pancreatic tumor tissue (Figure 2-1).  
 Consistent with a previous report that none of the PAK isoforms are 
expressed in normal, human pancreas tissue, two of the three normal tissue 
samples showed no PAK1 expression (25). Weak expression was observed for one 
sample.  In contrast, most of the tumor samples showed higher PAK1 expression 
levels when compared to normal tissue. Four of seven tumor samples showed 
strong PAK1 expression. Two out of seven showed expression similar to the weak 
expression observed for the only normal sample that exhibited PAK1 expression. 
Only one of the seven tumor samples showed a weaker expression than the normal 
sample.  These results suggest that PAK1 protein overexpression is found in a 
subset of pancreatic tumors.
 
I also examined PAK1 protein expression in a panel of pancreatic tumor cell 
lines with a PAK1 isoform-specific antibody (Figure 2- 2).  Consistent with the tumor 
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analysis results, PAK1 expression was observed in all seventeen cell lines. Several 
cell lines showed robust PAK1 expression, including the KRAS mutant CFPac-1, 
Panc-1, and HPAC. Some cell lines showed moderate PAK1 expression.  
Furthermore, PAK4 expression was also observed in a smaller panel of pancreatic 
tumor cell lines, using a PAK4 isoform specific antibody (Figure 2-3).  Analogous to 
PAK1 protein expression in PDAC cell lines, a subset of cell lines showed robust 
PAK4 protein expression and others showed moderate PAK4 expression.  
 
2.2 PAK suppression and PDAC cell anchorage-dependent growth 
The aberrant expression of PAK1 and PAK4 prompted my further 
investigation into the significance of PAK in the in vitro growth properties of 
pancreatic cancer cells.  To address this question, PAK1 and PAK4 suppression in 
pancreatic cancer cells is required. I used five short hairpin, lentiviral RNA-targeting 
vectors toward PAK1 in Panc-1 cells to determine which two shRNA vectors gave 
the best stable suppression of PAK1 protein expression (Figure 2-4). Surprisingly, 
PAK1sh5 increased PAK1 protein expression compared to Panc-1 cells expressing 
the non-specific, lentiviral RNA-targeting vector. The PAK1sh4 targeting vector 
completely depleted PAK1 protein. PAK1sh2 and PAK1sh3 both suppressed PAK1 
at comparable levels. Thus, PAK1sh2 and PAK1sh4 were used to suppress PAK1 
expression in additional pancreatic cancer cell lines (Figure 2-5). As expected, 
PAK1sh4 usually gave the better knockdown for each cell line. Weak PAK1 
expression was observed for pancreatic cancer cell lines expressing PAK1sh2.  To 
determine which shRNA vectors gave the best stable suppression of PAK4 protein 
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expression, I used five short hairpin (shRNA), lentiviral RNA-targeting vectors toward 
PAK4 in Panc-1 cells (Figure 2-6). None of the vectors increased PAK4 protein. The 
PAK4sh2 targeting vector depleted PAK4 protein the best compared to Panc-1 cells 
expressing the non-specific, lentiviral RNA-targeting vector. PAK4sh1, PAK4sh4, 
and PAK4sh5 all suppressed PAK4 at comparable levels. Therefore to be consistent 
with PAK1 suppression, PAK4sh2 and PAK4sh4 were used to suppress PAK4 
expression in additional pancreatic cancer cell lines (Figure 2-7). Both vectors, 
PAK4sh2 and PAK4sh4 usually gave comparable PAK4 suppression for each cell 
line.  
The anchorage-dependent proliferative potential of pancreatic cancer cell 
lines depleted of PAK1 and PAK4 was measured by a standard (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT viability assay and cell 
proliferation assay.  Only PAK1sh4 expressing cells showed a significant decrease 
in proliferation after seven days in the Panc-1 cell line (Figure 2-8). For the MiaPaca-
2 and CFPac-1 cell lines, there was no significant difference between the cells 
expressing the control vector and the cells expressing the PAK1 knockdown vectors 
(Figure 2-8). Likewise, there was no significant change observed between the cells 
expressing the control vector and the cells expressing the PAK4 knockdown vectors 
for the Panc-1, MiaPaca-2, and CFPac-1 cell lines (Figure 2-9). Thus, PAK1 
overexpression is essential for the anchorage-dependent growth of one of three cell 
lines evaluated. On the other hand, PAK4 expression is not essential for the 
anchorage-dependent growth of all three cell lines tested. 
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2.3 PAK suppression and PDAC cell anchorage-independent growth 
Although PAK1 depletion did not have a robust effect on the proliferative 
capacity of most of the pancreatic cancer cell lines and PAK4 depletion did not show 
a significant effect on the proliferative capacity of any of the cell lines tested, PAK 
depletion may have a greater significance for pancreatic carcinoma cell anchorage-
independent growth. Thus, I determined the ability of PAK1-depleted pancreatic 
tumor cells to form colonies of proliferating cells in soft agar, which is a measure of 
the ability of cells to proliferate in the absence of attachment. Normal cells lack this 
ability, whereas tumor cells have escaped the requirement for attachment. The soft 
agar assay is considered the best in vitro assay that correlates with tumorigenic 
growth of cells in vivo.  I determined that there was a moderate reduction in colony 
formation for Panc-1 cells expressing PAK1sh2 and a significant reduction in colony 
formation for Panc-1 cells expressing PAK1sh4, corresponding to the protein level 
knockdown of each vector (Figure 2-10). PAK1 suppression in MiaPaca-2 cells did 
not reduce colony formation and some instances resulted in a slight increase (Figure 
2-10).  
These results parallel to the proliferative capacity of PAK1 inhibited MiaPaca-
2 cells observed previously. Surprisingly, PAK1 inhibition in the CFPac-1 cell line 
showed a robust reduction in colony formation for cells expressing either the 
PAK1sh2 or the PAK1sh4 vector (Figure 2-10). These results are opposite to the 
proliferative capacity of PAK1 depleted CFPac-1 cells on plastic. Panc-1 cells 
expressing the PAK4sh2 vector showed a moderate reduction in colony formation; 
however, Panc-1 cells expressing the PAK4sh4 vector showed no change (Figure 2-
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11). These results correspond to the protein level knockdown of each vector. 
Contrastingly, PAK4 suppression in MiaPaca-2 cells showed no change for cells 
expressing the PAK4sh2 vector (Figure 2-11). A moderate reduction in colony 
formation was observed for MiaPaca-2 cells expressing the PAK4sh4 vector (Figure 
2-11). Similar to PAK1 inhibition in the CFPac-1 cell line, CFPac-1 cells expressing 
either the PAK4sh2 or the PAK4sh4 vector both showed a moderate reduction in 
colony formation (Figure 2-11).  These different results may reflect distinct roles of 
PAK1 and PAK4 in different pancreatic cancer cells.  Alternatively, there may be off-
target activities of the different shRNA vectors used that contribute to the different 
patterns of growth inhibition. Future studies where I rescue PAK expression with 
ectopic expression from RNAi-resistant cDNA constructs for PAK1 or PAK4 will be 
needed to address the specificity of my observations for PAK function in pancreatic 
cancer.
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CHAPTER 3.  
DISCUSSION 
In my studies, I addressed the question of whether PAK1 and/or PAK4 may 
be a useful therapeutic target for the treatment of pancreatic cancer.  The rationale 
for my studies is based on the fact that the current standard of care for pancreatic 
cancer, gemcitabine, is highly ineffective.  Pancreatic cancer is the 4th leading cause 
of cancer deaths in the US and essentially all who are diagnosed with this disease 
will die.  While signal transduction targeted therapies have made important impact 
on the treatment of other cancers (e.g., imatinib, vemurafenib), the one targeted 
therapy approved for pancreatic cancer, erlotinib, provided only marginal benefit and 
is not currently used.  My rationale for studying PAK1 is based on three previous 
findings.  First, one study found that Vav1, an activator of the Rac small GTPase, is 
overexpressed and required for pancreatic cancer tumorigenic growth.  They also 
found that Vav1 activated Rac and its downstream effector, PAK1, although they did 
not determine if Rac or PAK1 were required for pancreatic cancer growth.  Second, 
two downstream effectors of the K-Ras oncoprotein (PI3K and Tiam1), that is 
mutationally activated in greater than 90% of pancreatic cancers, can lead to 
activation of Rac and PAK1.  PI3K production of PIP3 can then cause activation of 
the RacGEF P-Rex1, leading to Rac activation.  Tiam1 is a RacGEF that has been
shown in mouse models of cancer to be required for RAS-induced skin tumor 
formation. Third, PAK1 has been shown in cell culture studies to be a positive 
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regulator of MEK and AKT, key components of Ras effector signaling.  Finally, there 
is evidence for the overexpression and contribution of PAK1 overexpression to other 
cancers.  All these findings provide the rationale for my studies to validate PAK1 in 
pancreatic cancer.  
In this study, I provide evidence to support further analyses investigating the 
significance of PAK1 and potentially PAK4 as drivers in pancreatic cancer growth 
and PAK1 and PAK4 inhibitors as a novel therapeutic approach for the treatment of 
this deadly disease.  My analyses of human tissue samples provide strong 
preliminary evidence that PAK1 protein has a higher incidence of aberrant 
overexpression in tumor versus normal tissue. These findings are surprising 
because a study by Arias-Romero et al revealed no transcriptional expression of all 
six PAK family members in normal pancreas tissue based on SAGE (serial analysis 
of gene expression), and suggests that the high levels of PAK1 protein that I found is 
aberrant and tumor-specific (25). Moreover, SAGE revealed widespread distribution 
of the PAK family members in almost all normal human tissues examined with the 
exception of the pancreatic tissue. My studies only evaluated PAK1 protein 
expression in a limited number of patient tumors.  Consequently, a more 
comprehensive evaluation of a larger number of tumors are needed to determine if 
PAK1 protein expression and other PAK isoforms are associated with specific 
genetic mutations in pancreatic cancer, which may give me an idea of how 
overexpression may be occurring.  Also, a comparison of primary and metastatic 
pancreatic tumors may determine if overexpression occurs during primary tumor 
formation or if it is associated with progression to metastatic cancer. 
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The aberrant PAK protein expression observed in the PDAC cell lines not 
only coincided with the tumor analysis results, but also further validated the 
importance of PAK1 as a therapeutic target for pancreatic cancer treatment. In fact, 
a recent study revealed that high PAK1 protein levels may predict tamoxifen 
insensitivity (26). Together, this study and the PAK1 protein overexpression 
observed in both the PDAC cell lines and patient tumors raise the question: Does 
the aberrant expression of PAK1 promote pancreatic cancer resistance to 
chemotherapeutic agents? An important future study will be to determine if PAK1 
inhibition will enhance the sensitivity of pancreatic tumor cells to gemcitabine. 
My study furthermore provides strong preliminary evidence regarding the 
significance of PAK in the in vitro growth properties of pancreatic cancer cells.  
Further studies of the consequences of PAK knockdown, specifically PAK1 and 
PAK4, on the growth of pancreatic cancer cell lines in vivo now need to be done.  
This could involve the standard nude mouse subcutaneous tumor xenograft studies.  
Even better would be the use of orthotopic tumor models where pancreatic tumor 
cells are inoculated into the pancreas.  In these models, pancreatic cancers cells 
can invade and metastasize to organs that are seen in the cancer patient.  This 
model would then determine if PAK is important for initial primary tumor growth as 
well as the invasive and metastatic properties.  Another approach for in vivo 
validation of PAK would be to perform a conditional loss of PAK in pancreatic tissue 
in the widely used mutant KRAS/p53 mouse model of pancreatic cancer formation.  
In this model, if PAK is lost concurrently with KRAS activation, it would then 
determine if PAK is required for tumor progression. A more relevant study for cancer 
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treatment will be to use inducible shRNA for PAK1 to then silence PAK1 expression 
in already developed pancreatic tumors. 
Another important future study to validate PAK can be the study of a 
pharmacologic inhibitor of PAK to test in mouse models of pancreatic cancer.  
Recently, a PAK1 inhibitor was described and shown to have anti-tumor activity.  I 
could use this inhibitor to treat preformed human xenograft tumors or the mouse 
tumors that develop in the KRAS/p53 mouse model.  I would then determine if tumor 
progression is reduced to increase mouse survival or if tumor regression is seen.  If 
tumor regression is seen, then I can determine if this is occurring because the loss 
of PAK1 is needed for cell survival and blocking PAK1 is causing apoptosis.   
Although my evaluation of PAK1 and PAK4 in pancreatic cancer cell lines 
was limited, some conclusions regarding PAKs potential as therapeutic targets can 
be inferred and these inferences prompt further investigation. Because I found that 
PAK1 overexpression is important for the anchorage-dependent growth of only one 
of three cell lines evaluated, this suggests that there may be a subset of pancreatic 
cancer cells that are dependent on PAK1 for anchorage-dependent growth and a 
subset that are not dependent. These findings are not completely shocking, as a 
recent study classified cancer cell lines into K-Ras dependent and K-Ras 
independent groups (27). Furthermore, I only used shRNA suppression of PAK1 
and, RNAi suppression is not a complete knock out of the gene. Therefore, residual 
PAK1 protein may be sufficient in certain cell lines to support PAK activity. In 
addition, rescue studies must also be completed to confirm that there are no off-
target activities of the shRNA vectors.  Although it is unlikely, other PAK isoforms 
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could potentially compensate for PAK1 and suppression. PAK4 overexpression was 
not important for the anchorage-dependent growth of the cell lines tested, which is 
not completely surprising because PAK4 has been more closely linked to metastatic 
and invasive properties of cells. Likewise, the data regarding anchorage-
independent growth suggests that there may also be a subset of pancreatic cancer 
cells that are dependent on PAK1 for anchorage-independent growth and a subset 
that are not dependent. Again, additional studies are required to deduct residual 
PAK activities, off-target activities, and other PAK isoform compensation. 
Nevertheless, these findings support further analysis using a larger panel of PDAC 
cell lines. 
In summary, I believe that my preliminary studies provide evidence to 
continue the study of PAK1 and PAK4 in pancreatic cancer.  Because PAKs are   
protein kinases, they are much more of druggable targets than mutant K-Ras.  So, if 
further studies provide strong evidence for the role of PAK1 and/or PAK4 in 
pancreatic cancer, PAK1 and/or other PAK isoforms may finally give us the anti-Ras 
drug that has been searched for in the last 30 years.  
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CHAPTER 4.  
METHODS 
 
Antibodies, Primary Tumors, and Cell Culture  
Polyclonal antibodies for PAK1 (cat. No, vendor) and PAK4 (cat. No, vendor), 
specifically, were obtained from Cell Signaling Technology Inc. Monoclonal GAPDH 
antibody was obtained from BD Bioscience. 
Normal pancreas and tumor tissue were provide by Jen Jen Yeh, M.D, at 
UNC School of Medicine. All cell lines (Panc-1, MiaPaca-2, and CFPac-1) were 
reported to be derived from human pancreatic duct carcinoma and obtained from the 
American Type Culture Collection. Panc-1 and MiaPaca-2 cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal calf 
serum. CFPac-1 cells were maintained in RPMI 1640 supplemented with 10% fetal 
calf serum. All cell lines were grown under standard culture conditions (5% CO2, 
95% air in humidified chamber at 37°C). 
 
Anchorage-dependent proliferation assay 
 To monitor the contribution of PAK to tumor cell anchorage-dependent 
growth, confluent cell cultures were trypsinized and seeded into 96-well plates in 
concentrations of 3x103 cells/well. After 1, 3, 5, and 7 days, cells were stained with 5 
mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and
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incubated at 37°C for 4 h. Fifty µl of vehicle (DMSO) was added to each well after 
aspirating MTT. The absorbance of the solution was measure using a 
spectrophotometer. The average number of cells on duplicate wells was calculated. 
 
Soft agar colony formation assay 
 Confluent cell cultures were trypsinized and seeded into 6-well plates in 
concentrations of 5x103 cells/well as single cell suspensions in 0.3% bacto-agar in 
complete growth medium. The single cell suspensions were layered on top of 0.6% 
bacto-agar in complete growth medium. After 2-4 weeks, colonies were stained with 
2 mg/ml MTT and the average number of colonies on duplicate dishes was 
calculated using ImageJ. 
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CHAPTER 5.  
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. PAK protein structure. PAKs (p21-activated kinases) were first 
identified in screens for Rac and Cdc42 effectors and independently as a proteinase-
activated kinase [1, 2]. There are six human PAK isoforms subdivided into Group I 
(PAK1-3) or Group I (PAK4-6). All PAKs are characterized by an N-terminal 
regulatory domain and a highly conserved C-terminal kinase domain. Overall 
sequence identity is indicated at the left and kinase domain sequence identity within 
each Group is indicated below the kinase domain. The regulatory domains of all 
PAKs consist of Rho GTPase-binding domain (RBD) and several proline-rich regions 
that serve as docking sites for SH3 domain-containing proteins. Group I Paks 
additionally possess an autoinhibitory domain (AID) overlapping with the RBD and a 
binding site for the PIX guanine nucleotide exchange factors. 
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Figure 2.1. PAK1 protein expression in pancreatic tissue.  Normal or 
pancreatic tumor tissues were lysed and resolved by SDS-PAGE.  Blot 
analyses were done with anti-PAK1 antibody and anti-GAPDH antibody to 
verify equivalent loading of total protein. 
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Figure 2.2. PAK1 protein expression in PDAC cell lines.  The indicated 
cell lines were lysed and resolved by SDS-PAGE.  .  Blot analyses were 
done with anti-PAK1 antibody and anti-GAPDH antibody to verify 
equivalent loading of total cellular protein. 
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Figure 2.3. PAK4 protein expression in PDAC cell lines. The indicated 
cell lines were lysed and resolved by SDS-PAGE.   Western blot analyses 
were done with anti-PAK4 antibody and anti-GAPDH antibody to verify 
equivalent loading of total cellular protein.  
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Figure 2.4. Evaluation of lentivirus vectors expressing shRNA 
targeting human PAK1. Lentivirus-based shRNA vectors targeting 
different sequences of human PAK1were obtained from the UNC vector 
core and were stably-infected into Panc-1 cells, followed  by puromycin 
selection, with multiple drug-resistant colonies pooled together. Blot 
analyses were done with anti-PAK1 antibody and anti-GAPDH antibody to 
verify equivalent loading of total cellular protein.  The sh2 and sh4 shRNA 
vectors showed the most consistent and reproducible suppression of 
PAK1 protein expression and were utilized for all subsequent studies.  
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Figure 2.5. PAK1 suppression in pancreatic cancer cells. Lentivirus- 
shRNA vectors sh2 or sh4 were stably-infected into the indicated pancreatic 
carcinoma cell line followed  by puromycin selection, with multiple drug-
resistant colonies pooled together. Blot analyses were done with anti-PAK1 
antibody and anti-GAPDH antibody to verify equivalent loading of total cellular 
protein.   
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Figure 2.6. Evaluation of lentivirus vectors expressing shRNA targeting 
human PAK1. Lentivirus-based shRNA vectors targeting different 
sequences of human PAK4 were obtained from the UNC vector core and 
were stably-infected into Panc-1 cells followed  by puromycin selection, with 
multiple drug-resistant colonies pooled together. Blot analyses were done 
with anti-PAK1 antibody and anti-GAPDH antibody to verify equivalent 
loading of total cellular protein.  The sh2 and sh4 shRNA vectors showed the 
most consistent and reproducible suppression of PAK4 protein expression 
and were utilized for all subsequent studies.  
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Figure 2.7. PAK4 suppression in pancreatic cancer cells. Lentivirus- 
shRNA vectors sh2 or sh4 were stably-infected into the indicated 
pancreatic carcinoma cell line, followed by puromycin selection, with 
multiple drug-resistant colonies pooled together. Blot analyses were done 
with anti-PAK4 antibody and anti-GAPDH antibody to verify equivalent 
loading of total cellular protein.   
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Figure 2.8. PAK1 suppression does not impair anchorage-dependent 
proliferative.  The proliferation of the indicated pancreatic cancer cell lines 
depleted of PAK1 was measured by a standard MTT viability assay. Data 
shown are representative of at least three independent experiments.  
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Figure 2.9. PAK1 suppression does not impair anchorage-dependent 
proliferative.  The proliferation of the indicated pancreatic cancer cell lines 
depleted of PAK4 was measured by a standard MTT viability assay. Data 
shown are representative of at least three independent experiments. 
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Figure 2.10. PAK1 suppression impairs anchorage-independent 
proliferation of some PDAC cell lines.  The colony formation in soft agar of 
the indicated  pancreatic cancer cell lines depleted of PAK1 was quantitated 
approximately 14 days. Data shown are representative of at least three 
independent experiments. Error bars are the mean ± standard deviation for 
two duplicate dishes.  
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Figure 2.11. PAK4 suppression impairs anchorage-independent 
proliferation of some PDAC cell lines.  The colony formation in soft agar of 
the indicated pancreatic cancer cell lines depleted of PAK4 was quantitated 
after approximately 14 days. Data shown are representative of at least three 
independent experiments. Error bars shown are the mean ± standard 
deviation for duplicate dishes.  
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